A Johnson & Johnson gene therapy in development for an inherited vision-loss disorder has failed a Phase 3 study, the latest clinical research setback for a rare eye disease that so far has no ...
TRAILBLAZER-2, a Phase 3 study, has enrolled 1,600 participants. Prescreening with plasma p-tau-181 helped select people with both amyloid and tau pathology. A secondary prevention trial, ...
Rezolute’s stock has plunged 87% after the company’s rare disease drug flunked the final clinical test ahead of a planned approval application. The company had been evaluating ersodetug as a treatment ...
Eli Lilly already posted preliminary data showing its obesity drug, Zepbound topped Novo Nordisk’s Wegovy on measures of weight loss in a head-to-head clinical trial. More detailed results, including ...
BridgeBio has vaulted over the success bar it set for a phase 3 rare disease trial, linking the candidate to significant improvements on biomarker and clinical outcomes to tee up a filing for FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback